ADAPTIN BIO, INC. - 10-Q Filing

Adaptin Bio, Inc. reports Q3 2026 financial results featuring significant equity activity including consultant grants and follow-on offering warrants.

SEC EDGAR ·

Tickers: $APTN

Read the full article at SEC EDGAR

More Regulatory news